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n vitro delivery of the diphtheria toxin catalytic (C) domain
from the lumen of puriﬁed early endosomes to the external
milieu requires the addition of both ATP and a cytosolic
translocation factor (CTF) complex. Using the translocation
of C-domain ADP-ribosyltransferase activity across the endo-
somal membrane as an assay, the CTF complex activity was
650–800-fold puriﬁed from human T cell and yeast extracts,
respectively. The chaperonin heat shock protein (Hsp) 90 and
thioredoxin reductase were identiﬁed by mass spectrometry
sequencing in CTF complexes puriﬁed from both human T
cell and yeast. Further analysis of the role played by these
two proteins with speciﬁc inhibitors, both in the in vitro
translocation assay and in intact cell toxicity assays, has
I
 
demonstrated their essential role in the productive delivery
of the C-domain from the lumen of early endosomes to the
external milieu. These results conﬁrm and extend earlier
observations of diphtheria toxin C-domain unfolding and
refolding that must occur before and after vesicle membrane
translocation. In addition, results presented here demonstrate
that thioredoxin reductase activity plays an essential role in
the cytosolic release of the C-domain. Because analogous
CTF complexes have been partially puriﬁed from mammalian
and yeast cell extracts, results presented here suggest a
common and fundamental mechanism for C-domain trans-
location across early endosomal membranes.
 
Introduction
 
Diphtheria toxin (DT;* 58 kD) is a typical single-chain AB
toxin composed of three functional domains: the amino-
terminal catalytic (C) domain corresponds to fragment A
(21 kD), and the transmembrane (T) and carboxy-terminal
receptor-binding domains comprise fragment B (37 kD) of
the toxin (Choe et al., 1992). A disulfide bond between
Cys186 and Cys201 subtends a protease-sensitive loop and
connects fragment A with fragment B. Furin-mediated cleavage
within this loop and retention of the disulfide bond have
been shown to be prerequisites for intoxication of eukaryotic
cells (Ariansen et al., 1993; Tsuneoka et al., 1993). Substitution
of the native receptor domain with human interleukin-2
(IL-2) has resulted in the formation of a fusion protein toxin,
 
DAB
 
389
 
IL-2, whose cytotoxic action is specifically targeted only
to cells expressing the high affinity IL-2 receptors (Bacha et
al., 1988; Waters et al., 1990; Ratts and vanderSpek, 2002).
Because DAB
 
389
 
IL-2 binds with greater affinity to its receptor
compared with native DT, this fusion protein toxin has
proven to be an effective and novel probe for studying inter-
nalization of the C-domain by target cells (Williams et al.,
1990). Although much is known about the mechanisms of
receptor-binding and receptor-mediated endocytosis of native
DT and the DT-related fusion proteins, little is known
about the precise molecular mechanisms of C-domain trans-
location across the endosomal membrane and its release into
the cytosol.
Unfolding of the DT C-domain was first postulated as a
prerequisite for translocation by Kagan et al. (1981) and
Donovan et al. (1981). The necessity for complete denaturation
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of the DT C-domain before translocation was then indi-
rectly demonstrated by Wiedlocha et al. (1992) and by
Falnes et al. (1994). At present, there are two conflicting hy-
potheses for translocation of denatured DT C-domain
across the early endosomal membrane. Studies using artifi-
cial lipid bilayers suggest that the DT T-domain itself exhib-
its chaperonin-like properties and is solely sufficient to pro-
mote C-domain delivery across the bilayer (Oh et al., 1999;
Ren et al., 1999). In contrast, studies using partially purified
early endosomes that were preloaded with toxin suggest that
C-domain translocation across the vesicle membrane is de-
pendent on ATP and the presence of cytosolic components
which include 
 
 
 
-COP (Lemichez et al., 1997). Because pro-
tease digestion patterns of DT inserted into planar lipid bi-
layers differ from those of DT inserted into the plasma
membrane (Moskaug et al., 1991; Cabiaux et al., 1994), it
seems likely that interaction(s) between the toxin and pro-
teins associated with the endosomal membrane (e.g., recep-
tor) influence the orientation and/or stoichiometry of inser-
tion of the T-domain and translocation of the C-domain. In
addition, Ren et al. (1999) and Hammond et al. (2002)
have shown that although the DT T-domain has chapero-
nin-like properties, it has a significantly greater affinity for
other molten globule-like polypeptides compared with its
own C-domain.
To further define the requirements of C-domain translo-
cation across the endosomal membrane, we have used an in
vitro C-domain translocation assay essentially as described
by Lemichez et al. (1997). This assay uses purified early en-
dosomes that have been preloaded with DAB
 
389
 
IL-2 and
monitors the translocation of ADP-ribosyltransferase activ-
ity from the endosomal lumen to the external milieu. We
have used translocated ADP-ribosyltransferase activity to
monitor the purification of cytosolic components that are
required for this process. In the present paper, we demon-
strate by mass spectrometry (MS) sequence identification
and the effect of specific inhibitors that the chaperonin heat
shock protein (Hsp) 90 and thioredoxin reductase (TrR-1)
are components of a cytosolic translocation factor (CTF)
complex that is essential for the translocation and release of
C-domain from early endosomes. Furthermore, the identifi-
cation of CTF complex homologues in partially purified
yeast extracts suggests that DT C-domain translocation may
proceed by a fundamental mechanism of entry.
 
Results
 
Partial purification of the DT C-domain CTF complex
 
The requirements for DT C-domain translocation across the
early endosomal membrane and release into the external mi-
lieu were monitored using an in vitro translocation assay
modified from Umata et al. (1990) and Lemichez et al.
(1997). The early endosomal compartment of HUT102
6TG cells was preloaded with DAB
 
389
 
IL-2 in the presence of
bafilomycin A1. Early endosomes were purified by sucrose
density gradient centrifugation, and then incubated in the
presence of ATP and cytosolic extracts from either HUT102
6TG cells or yeast. After incubation at 37
 
 
 
C, translocation
of the C-domain across the endosomal membrane and re-
lease into the external medium was monitored by ADP-ribo-
syltransferase activity of both the pellet and supernatant
fluid fractions after ultracentrifugation. The [
 
32
 
P]ADP ribo-
sylation of elongation factor 2 (EF-2) was measured by auto-
radiography of SDS-PAGE of reaction mixtures (Chung and
Collier, 1977). The limit of sensitivity of this assay is in the
range of 10
 
 
 
14
 
–10
 
 
 
16
 
 M C-domain, a level well below that
of detection by immunoblot (unpublished data).
As shown in Fig. 1 A, on dilution of bafilomycin A1 and
the addition of both ATP and cytosolic extracts to the reac-
tion mixture, the C-domain is translocated across the endo-
somal membrane and released into the external medium.
Moreover, preboiling the cytosolic extracts before their addi-
Figure 1. Partial purification of cytosolic proteins required to 
mediate DT C-domain translocation from the lumen of early 
endosomes in vitro. (A) Early endosomes from human T cells 
(HUT102/6TG), preloaded with DAB389IL-2, were incubated for 
30 min at 37 C with 2 mM ATP (A) and/or 4  g HUT102/6TG crude 
cytosol (C). C* denotes heat inactivation of cytosol before incubation 
with endosomes. Endosomes were pelleted, and the supernatant 
fraction (S) was assayed for DT C-domain ADP-ribosyltransferase 
activity by measuring the incorporation of [
32P]NAD
  into 
AD[
32P]ribosyl-EF-2 after 7% SDS-PAGE and autoradiography. 
(B) Time course for translocation of ADP-ribosyltransferase activity 
from DA189(VSV-G)B389IL-2 across the early endosomal membrane. 
Translocations were performed as described above, except the 
reactions were incubated at different temperatures (0, 15, and 37 C) 
for 15, 30, and 45 min. Both the supernatant and the pellet 
fractions were assayed for ADP-ribosyltransferase activity, and the 
autoradiographic signals were measured by densitometry. The sum 
of densitometry units from each pair of supernatant fluid and pellet 
fractions is plotted as the percentage of activity in the supernatant 
fractions at that time point. (n   3; error bar denotes SD).T
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tion to the reaction mixture abolishes C-domain transloca-
tion. These results suggest that the C-domain translocation
across the membrane of early endosomes requires cytosolic
protein(s). The time course of C-domain translocation was
examined using the epitope-labeled fusion protein toxin
DAB
 
189(VSV-G)
 
B
 
389
 
IL-2. The cytotoxic potency of the
epitope-tagged fusion toxin is almost identical to that of
DAB
 
389
 
IL-2 (IC
 
50
 
 
 
 
 
 3 
 
 
 
 10
 
 
 
11 
 
M vs. 4 
 
 
 
 10
 
 
 
12 
 
M). As
shown in Fig. 1 B, the ADP-ribosyltransferase activity as
measured by densitometry of the combined 
 
32
 
P-labeled EF-2
from each paired pellet and supernatant fluid fraction is
plotted as percentage of ADP-ribosyltransferase activity in
the supernatant fluid. As can be seen, translocation of the
C-domain is linear for up to 45 min, at which time 
 
 
 
80% of
the total activity is found in the supernatant fluid fraction.
As reported by Lemichez et al. (1997), whereas ADP-ribo-
syltransferase activity was translocated to the external me-
dium, cointernalized HRP activity was found to remain in
the pellet fraction throughout the incubation period (un-
published data). These results strongly suggest that C-domain
translocation is specific, and not the result of spontaneous
endosomal lysis during the incubation period. Finally, in the
presence of added ATP and cytosolic extracts, the transloca-
tion of the C-domain is dependent on membrane fluidity
and does not occur at temperatures below 15
 
 
 
C.
To rule out the possibility that the crude T cell and yeast
extracts contained an allosteric regulator(s) of vesicular ATP-
ase activity rather than protein(s) that are required for
C-domain translocation, early endosomes were charged with a
70-kD dextran conjugated with the pH-sensitive fluorescent
dye, SNARF-1. As shown in Fig. 2 A, compared with pH
7.5, the fluorescence emission of 1 ng/ml SNARF-1 is de-
creased approximately fourfold at pH 4.5. As measured by
the quenching of fluorescence emission of SNARF-1, in
vitro acidification of the early endosomal lumen occurs on
dilution of bafilomycin A1 and requires the addition of 2
mM ATP to the reaction mixture (Fig. 2 B). Moreover, the
time course for the acidification of early endosomes in vitro
is virtually identical after the addition of either 2 mM ATP
or 2 mM ATP plus partially purified T cell CTF complex.
 
Partial purification of human T cell and yeast cytosolic 
factors required for the in vitro translocation 
of ADP-ribosyltransferase activity across 
the membrane of early endosomes
 
Because C-domain translocation across the endosomal vesi-
cle membrane requires the addition of cytosolic components
to the reaction mixture, we used translocation of ADP-
ribosyltransferase activity to monitor the partial purifica-
tion of the active component(s) from both human T cell
(HUT102/6TG) and yeast (NLY22
 
 
 
) extracts. After DEAE
anion exchange chromatography, translocation-active frac-
tions (150 mM–190 mM NaCl) were pooled and applied to
a Sephacryl
 
®
 
 200 sizing column. The translocation-active
fractions (250–100 kD) were pooled and further fraction-
ated by Mono Q HPLC under conditions free of reducing
agents. The translocation-active fraction was found to elute
from the Mono Q column at 27.3 mS. As shown in Fig. 3
A, after fractionation on Mono Q, CTF complex activity
from human T cell and yeast cell extracts was increased by
650-fold and 800-fold, respectively. Further analysis of the
Mono Q-pooled fractions by SDS-PAGE and colloidal
Coomassie staining revealed multiple protein bands ranging
in apparent molecular mass from 
 
 
 
12–100 kD (Fig. 3 B).
 
Identification of individual components 
of the CTF complex
 
Tryptic peptides from “in-gel” digestion of individual protein
bands resolved by SDS-PAGE were subjected to analysis by
mass spectroscopy using matrix-assisted laser desorption/ion-
ization–time-of-flight (MALDI-TOF) and nano-electrospray
ionization (ESI) quadrupole/orthogonal TOF spectrometers
(Jensen et al., 1999). Peptide maps and tandem MS sequence
Figure 2. The in vitro acidification of early endosomes requires ATP and does not require any cytosolic protein factors. (A) Fluorescence 
emission of 1 ng/ml SNARF-1 70 kD dextran conjugate standards at pH 7.5 and 4.5 was measured at an excitation wavelength of 534 nM and 
an emission wavelength of 645 nM. (B) Purified early endosomes preloaded with the pH-sensitive SNARF-1 70 kD dextran conjugates were 
incubated in translocation assay buffer for 20 min at 37 C with 2 mM ATP and/or 0.1  g/ L of Mono Q-purified cytosol. In each instance, assays 
were performed in triplicate and fluorescence was monitored using a fluorescence detector (model 650S; PerkinElmer). Error bars denote SD.T
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data allowed for the unequivocal identification of Hsp 90 (
 
 
 
and 
 
 
 
) and TrR-1 in the partially purified CTF complex
mixture from human T cells (Fig. 4; Table I). Importantly,
the corresponding yeast homologues, Hsp 82 and TrR-1, as
well as thioredoxin peroxidase, were identified in the partially
purified CTF complex from yeast cells (Table I). The cumu-
lative peptide coverage for each protein identified through
LC-MS/MS sequencing was between 65 and 85% of the to-
tal protein (Table S1, available at www.jcb.org/cgi/content/
full/jcb.200210028/DC1). Ions unassigned in the LC-MS/
MS spectra were indicative of truncation, sequence variation,
and/or post-translational modification.
 
Hsp 90 is essential (but not sufficient) for C-domain 
translocation in vitro
 
To determine whether Hsp 90 was a component of the CTF
complex and to establish a functional role for this chapero-
nin in C-domain translocation, we conducted a series of ex-
periments to examine the effects of using both polyclonal
anti-Hsp 90 antibodies and specific inhibitors. As shown in
Fig. 5 A, either immunoprecipitation of Hsp 90 from the
CTF complex or addition of anti-Hsp 90 to the CTF com-
plex before initiation of the translocation reaction resulted in
marked loss of ADP-ribosyltransferase activity in the super-
natant fluid fraction. There was no significant loss of ADP-
ribosyltransferase activity in the pellet fractions, which
argues against the possibility of any translocated but non-
refolded pool of DT C-domain. Because attempts to recon-
stitute the immunodepleted CTF complex with human
recombinant (hr) Hsp 90 failed to restore translocation ac-
tivity, we conclude that additional, as yet unknown, pro-
tein(s) required for translocation was also removed by im-
munoprecipitation (Fig. 5 B).
Because geldanamycin and radicicol are well-known in-
hibitors of Hsp 90, we next examined the effect of these two
Figure 3. The partial purification 
of CTFs results in the increase of 
translocation in vitro specific activity. 
(A) Translocation in vitro specific activity 
of CTFs increases after each stage of 
purification. Reactions were performed 
as described in Fig. 1, and only the 
ADP-ribosyltransferase activity of the 
supernatant fluid fractions is shown. CE, 
crude extract; DEAE, DEAE-Sepharose 
anion exchange chromatography 
(150–190 mM NaCl fractions); S200, 
Sephacryl
® 200 sizing chromatography 
(250–100-kD fractions); MQ, Mono Q 
anion exchange chromatography 
(27.3-mS fractions). (B) Colloidal 
Coomassie stained 10% SDS-PAGE 
protein band profiles after Mono Q anion 
exchange chromatography. Partially 
purified CTF complex fractions from 
both T cells and yeast cells were eluted 
at a conductance of 27.3 mS.
 
Table I. 
 
Summary of the data obtained for each putative CTF 
component identified in this work: MALDI, ESI-MS/MS,
LC-MS/MS, Western blot (WB), in vitro translocation assay (TA), 
and mammalian cell cytotoxicity assay (CA)
Putative CTFs Data obtained
 
Human T cell
(Hut 102/6TG)
Hsp 90 
 
 
 
MALDI, ESI-MS/MS, LC-MS/MS, WB, TA, CA
Hsp 90 
 
 
 
MALDI, ESI-MS/MS, LC-MS/MS, WB, TA, CA
TrR-1 MALDI, ESI-MS/MS, WB, TA, CA
Yeast (NLY22
 
 
 
)
Hsp 82 MALDI, ESI-MS/MS, WB, TA, CA
TrR-1 MALDI, LC-MS/MS, TA, CA
Thioredoxin
peroxidase (AHP1)
MALDI, ESI-MS/MST
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agents on C-domain translocation in vitro. These agents are
known to bind to the ATPase site of the chaperone and
block ATP hydrolysis, thereby inhibiting refolding and re-
lease of substrate (Grenert et al., 1997; Schulte et al., 1998).
Fig. 6 shows that neither the addition of geldanamycin nor
radicicol alone was capable of inhibiting C-domain translo-
cation. However, when both inhibitors were used in combi-
nation, C-domain translocation was inhibited. There are
several reports demonstrating the synergistic inhibitory ef-
fects of geldanamycin and radicicol on Hsp 90, and in-
hibition is thought to result from either the disruption of
substrate binding or the interaction with cochaperonins
(Rosenhagen et al., 2001). This phenomenon appears to be
Hsp 90-specific because the addition of hrHsp 90 to geldan-
amycin/radicicol-treated human T cell CTF complexes re-
stored C-domain translocation (Fig. 6). Interestingly, the
addition of rhHsp 90 to the geldanamycin/radicicol treated
CTF complex from yeast only partially restored C-domain
translocation in vitro, suggesting that these agents disrupt a
species-specific Hsp 82 cochaperone interaction necessary
for reconstitution of translocation activity.
 
TrR-1 is essential (but not sufficient) for DT C-domain 
translocation in vitro
 
Because TrR-1 was also identified by MS sequence analysis
of CTF complexes from human T cell and yeast extracts,
we have used both immunoprecipitation and specific in-
hibitors to demonstrate a functional role of TrR-1 in the
Figure 4. Identification of putative CTF(s) using MS. (A) Representative total ion chromatogram from an online capillary liquid chromatography 
mass spectrometric analysis of the in-gel tryptic digest after immunoprecipitation of the 84-kD band (Fig. 2 B and Fig. 5 B) from human 
partially purified CTFs using rabbit polyclonal anti-Hsp 90 antibodies. (B) Mass spectrum from LC-MS elution at time 19.5 to 20.5 min, as 
indicated by the shaded region in (A). Peaks are labeled with the m/z value, the charge state, the corresponding amino acid segment, and 
specification of the Hsp 90 isoform. (C) Tandem mass spectrum for m/z 575.98
4  (redundant sequence from Hsp 90   and  ; see inset on B). 
Complementary a and b (NH2-terminal derived) as well as y (COOH-terminal derived) ions are labeled in the spectrum with m/z value and 
charge state. All observed a, b, and y ions are indicated in the peptide diagram. Data were analyzed using BioAnalyst™ (Applied Biosystems) 
reconstruction algorithms. For initial screening and searches, acquired mass values were compared with theoretical protein digests using the 
Mascot search engine (Matrix Science Ltd.).T
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translocation and/or release of the C-domain from early
endosomes. As shown in Fig. 7 A, immunoprecipitation
of TrR-1 from human CTF complexes and 2
 
 
 
,5
 
 
 
-ADP-
Sepharose affinity chromatographic depletion of yeast
TrR-1 from CTF complex mixtures abolished C-domain
translocation in vitro. Because there was no significant loss
of ADP-ribosyltransferase activity in the pellet fractions
(unpublished data), we conclude that there is no pool of
translocated but nonrefolded DT C-domain. Reconstitu-
tion experiments in which bovine recombinant (br) TrR-1
was added back to TrR-1-depleted CTF complexes, from
both T cell and yeast, failed to restore C-domain transloca-
tion (unpublished data). Because these experiments were
performed under conditions known to reduce the inter-
chain disulfide bond between the C- and T-domains, these
results suggest that TrR-1 is a component of a complex and
Figure 5. Hsp 90 is a component of the 
CTF complex. (A) Hut 102/6TG (H) and 
yeast NLY22
  (Y) partially purified CTF 
complexes were coincubated with 1  g 
anti-Hsp 90 and 1  g anti-Hsp 82 
antibodies, respectively, for 10 min at RT 
before standard analysis in the in vitro 
translocation assay. Analogously, CTF 
complexes were depleted of Hsp 90 or 
Hsp 82 by immunoprecipitation and 
assayed for translocation activity in vitro. 
Either partially purified CTF complex or 
hrHsp 90 was added back to Hsp 90-
depleted CTF complexes as indicated, 
and translocation activity in vitro was 
assayed. (B) Colloidal Coomassie-stained 
10% SDS-PAGE protein band profiles of 
immunoprecipitated human Hsp 90 (IP), 
marker (M). Arrow indicates Hsp 90 as 
identified by ESI LC-MS/MS analysis.
Figure 6. Hsp 90 is essential for mediating DAB389IL-2 C-domain translocation from the lumen of early endosomes to the external milieu. 
The Hsp 90-specific inhibitors, geldanamycin and radicicol, were preincubated with partially purified CTF complex as indicated for 15 min 
at RT before assaying for translocation activity in vitro. Excess partially purified HUT 102/6TG CTF complex and hrHsp 90 were added to 
geldanamycin/radicicol treated CTF complexes as indicated and assayed for translocation activity in vitro.T
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that another factor(s) essential for translocation was code-
pleted with TrR-1 (Fig. 7 B).
Next, we examined the effect of the TrR-1 stereo-specific
inhibitor cis-13-retinoic acid on C-domain translocation
(Schallreuter and Wood, 1989). The addition of cis-13-ret-
inoic acid, but not trans-13-retinoic acid, to either human or
yeast CTF complex mixtures resulted in the complete inhi-
bition of C-domain translocation in vitro under nonreduc-
ing conditions (Fig. 8). Importantly, the addition of excess
brTrR-1 to cis-13-retinoic–treated complex restored C-domain
translocation activity in vitro, suggesting that cis-13-retinoic
acid inhibition is TrR-1 specific. Finally, when assayed un-
der reducing conditions (20 mM DTT), cis-13-retinoic acid
had no effect on C-domain translocation (unpublished data).
Together, these results indicate that TrR-1 activity plays an
essential role in the translocation and/or release of the C-domain
from early endosomes.
 
Geldanamycin/radicicol and cis-13-retinoic acid 
protect HUT102 6TG cells from the cytotoxic action 
of DAB
 
389
 
IL-2
 
Because geldanamycin and radicicol were found to have a
synergistic effect in blocking the in vitro translocation of
ADP-ribosyltransferase from purified early endosomes, we
examined the ability of these agents to protect intact cells
from DAB
 
389
 
IL-2. A series of dose-response experiments
showed that neither the addition of 10 nM geldanamycin
nor 10 nM radicicol alone confer protection against the fu-
sion protein toxin. However, as seen in in vitro translocation
assays, these agents in combination (10 nM each) were able
to affect a two-log shift in the DAB
 
389
 
IL-2 dose-response
curve (IC
 
50
 
 
 
  
 
10
 
 
 
8
 
 M) compared with the untreated control
(IC
 
50
 
 
 
 
 
 5 
 
 
 
 10
 
 
 
10
 
 M). In a similar fashion, cis-13-retinoic
acid was found to affect a similar dose-dependent shift in the
DAB
 
389
 
IL-2 dose-response curve for HUT102 6TG cells
Figure 7. TrR-1 is a component of the CTF complex. (A) Hut 102/6TG (H) and yeast NLY22
  (Y) partially purified CTF complexes were 
depleted of TrR-1 by immunoprecipitation with anti-human TrR-1 antibodies or affinity purification using 2 ,5  ADP-Sepharose. TrR-1–depleted 
CTF complexes were then assayed for translocation activity in vitro under reducing conditions. Either partially purified CTF complex or brTrR-1 
was added back to TrR-1–depleted CTF complexes as indicated, and translocation activity in vitro was assayed. (B) Colloidal Coomassie-
stained 10% SDS-PAGE protein band profiles of 2 ,5  ADP-Sepharose affinity-purified yeast TrR-1 (AP), marker (M). Arrow indicates yeast 
TrR-1 as identified by ESI LC-MS/MS analysis.
Figure 8. TrR-1 function is essential for mediating DAB389IL-2 C-domain translocation from the lumen of early endosomes to the external 
milieu under nonreducing conditions. Partially purified CTF complex, both human and yeast, were assayed for translocation activity in vitro 
under nonreducing conditions using translocation buffer containing 10  M NADPH without DTT. The TrR-1 stereospecific inhibitor cis-13-
retinoic acid and the inactive trans-13-retinoic acid isomer were preincubated with partially purified CTF complex as indicated for 15 min 
at RT before assaying for translocation activity in vitro under nonreducing conditions. Excess brHsp 90 was added to c13RA-treated CTF 
complexes as indicated, and translocation activity in vitro was assayed under nonreducing conditions.T
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(unpublished data), confirming and extending early observa-
tions made by Sandvig and Olsnes (1981).
 
Discussion
 
In the present report, we demonstrate that the in vitro trans-
location of the DAB
 
389
 
IL-2 ADP-ribosyltransferase activity
across the membrane of early endosomes and its release into
the external milieu requires a CTF complex. Using translo-
cated ADP-ribosyltransferase activity as an assay, we have
partially purified the CTF complex from both human T cell
and yeast extracts. MS sequencing of individual protein
bands revealed by colloidal Coomassie staining of SDS-poly-
acrylamide gels has allowed the identification of Hsp 90 and
TrR-1 from human T cells, and the homologous Hsp 82
and TrR-1 from yeast extracts. A functional role for these
proteins in the translocation and/or cytosolic release of
ADP-ribosyltransferase activity was established through im-
munoprecipitation and the use of specific inhibitors.
After depletion of either Hsp 90 or TrR-1 from partially
purified human T cell and yeast CTF complexes, we were
not successful in reconstituting in vitro translocation of the
C-domain by the addition of hrHsp 90 or brTrR-1, either
alone or in combination. These results suggest that Hsp 90
chaperonin and TrR-1 are components of a complex(es)
that is (are) necessary for facilitating C-domain transloca-
tion across the early endosomal membrane. In marked
contrast, we were able to reconstitute in vitro C-domain
translocation activity in either geldanamycin/radicicol or
cis-13-retinoic acid treated CTF complexes by the addition
of recombinant proteins to the mixture. Together, these ob-
servations lead us to conclude that both the chaperonin Hsp
90 and TrR-1 are required for C-domain translocation, but
are not in themselves sufficient.
Hsp 90 is ubiquitously expressed and is known to be
a component of several multi-molecular chaperonin com-
plexes that are highly conserved in eukaryotes (Chang and
Lindquist, 1994). The interaction of Hsp 90 with other co-
chaperonins and the formation of discrete complexes is
known to mediate Hsp 90 substrate recognition (Caplan,
1999). Although Hsp 90 does not usually directly bind nor
refold nascent polypeptides, it is known to refold a growing
list of newly synthesized proteins including membrane-asso-
ciated protein kinases (Bijlmakers and Marsh, 2000). In
addition to its refolding activity, Hsp 90 complexes are
also known to regulate the trafficking of membrane-associ-
ated proteins through interactions with cytoskeleton motors
(Pratt et al., 1999).
The CTF complex is capable of refolding thermally dena-
tured DT fragment A in vitro, and refolding requires the
ATPase activity of Hsp 90 (unpublished data). However, the
inhibition of Hsp 90 ATPase activity by either geldanamy-
cin or radicicol alone does not inhibit translocation of ADP-
ribosyltransferase activity across the early endosomal mem-
brane. As such, it would appear that refolding of denatured
C-domain into an active conformation and translocation are
mutually exclusive events. The synergistic effects of geldana-
mycin and radicicol on the inhibition of ADP-ribosyltrans-
ferase translocation are of interest, and is consistent with
previous reports (Rosenhagen et al., 2001). It is possible that
when used in combination, these inhibitors result in either a
disruption of Hsp90 substrate recognition and/or the dis-
ruption of Hsp 90–cochaperone interactions, thereby lead-
ing to an inhibition of C-domain translocation. Although a
firm conclusion cannot yet be reached, the inability to re-
constitute yeast CTF complexes with mammalian factors
supports the later hypothesis. We are currently investigating
whether or not Hsp 90 interacts directly with the fusion pro-
tein toxin during translocation or is simply an architectural
component of the complex.
After furin-mediated nicking of the  -carbon backbone
of either DT or DAB389IL-2, retention of the interchain di-
sulfide bond between the C- and T-domains of the toxin
presumably is essential for insertion and threading of the de-
natured C-domain into and through the nascent channel
formed by the T-domain (vanderSpek et al., 1994). More-
over, post-translocation reduction of this disulfide bond is
also required for the release of the C-domain into the cyto-
sol because unreduced C-domain and membrane-inserted
T-domain are both targeted for proteolytic degradation
(Moskaug et al., 1993; Madshus et al., 1994). Indeed, the
pivotal role of this event is underscored by the observation
that reduction of this interchain disulfide bond is the rate-
limiting step in the diphtherial intoxication of eukaryotic
cells (Papini et al., 1993). Observations reported here con-
firm and extend these earlier findings, and strongly suggest
that TrR-1 is a component of the CTF complex required
for the release of the C-domain from the early endosome.
These observations also confirm and extend the earlier ob-
servations of Sandvig and Olsnes (1981), who reported that
retinoic acids inhibit the action of several AB toxins, includ-
ing DT, on eukaryotic cells.
Although the data reported here clearly demonstrate that
TrR-1 activity is required for at least the cytosolic release of
the DAB389IL-2 C-domain from purified early endosomes,
we cannot conclude whether or not TrR-1 is directly in-
volved in the reduction of the interchain disulfide bond. Be-
cause we have identified thioredoxin peroxidase in CTF
complexes purified from yeast, it is possible that TrR-1
functions indirectly through a cascade of reductases (e.g.,
thioredoxin; Moskaug et al., 1987).
It is widely accepted that anthrax lethal toxin and edema
factor, as well as the botulinum neurotoxins, must pass
through an acidic early endosomal compartment in order to
deliver their respective C-domain into the cytosol of tar-
geted cells. The unfolding of the C-domains of anthrax le-
thal factor (Wesche et al., 1998) and botulinum toxin sero-
type D (Bade et al., 2002), as well as the TrR-1–mediated
reduction of the botulinum neurotoxins (Kistner and Ha-
bermann, 1992; Bigalke and Shoer, 2000), have been postu-
lated to be prerequisites for their delivery to the cytosol.
Accordingly, the findings reported here may have wider im-
plications. Importantly, several protein complexes of similar
composition have been described in protein-trapping pro-
teomic analysis of yeast. For example, Ho et al. (2002) has
shown that cyclophilin-trapped complexes from yeast con-
tain Hsp 82, TrR-1, and Sec 27. Moreover, cyclophilin is
required for the cytosolic entry of HIV (Braaten et al.,
1996), the vacuolar import of fructose-1,6-bisphophatase
(Brown et al., 2001), and the activation of peroxiredoxinsT
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(Lee et al., 2001). It should also be noted that trafficking
mechanisms mediated by cyclophilin–Hsp 90 complexes are
synergistically affected by geldanamycin and radicicol
(Meyer et al., 2000). In aggregate, observations reported
here confirm and extend the hypothesis that multiple patho-
gens from diverse phylogenetic backgrounds, as well as
many of their virulence determinants have convergently
evolved to recruit host cell proteins (e.g., CTF complexes)
in order to facilitate their membrane translocation and re-
lease into the cytosol of eukaryotic cells.
Materials and methods
Cell culture
HUT1026TG cells (TIB 1620; American Type Culture Collection), were
maintained in RPMI 1640 (BioWhittaker) supplemented with 10% FBS
(HyClone), 2 mM glutamine (BioWhittaker), 50 IU/ml penicillin, and 50
 g/ml streptomycin (BioWhittaker) at 37 C in 5% CO2. Yeast strain
NLY22
  (a gift from Dr. Kevin Jarrell, Modular Genetics Inc., Lincoln, MA)
was maintained in YPD media (Difco
®) and on YPD agar plates at 30 C.
Purification of EF-2
EF-2 was partially purified using a procedure by Chung and Collier (1977).
After purification, fractions containing EF-2 were identified by ADP-ribo-
syltransferase using DAB389IL-2 (see In vitro ribosylation assay). EF-2 was
further purified by DEAE-Sepharose (Reactifs IBF) anion exchange chroma-
tography. EF-2 was eluted with a linear gradient, 0–200 mM NaCl, in 50
mM Tris-HCl, pH 8.0, 50 mM Mg(OAc)2, 0.1 M KCl, 4 mM CaCl2, 5 mM
2-ME and 1  g PMSF (Sigma-Aldrich) per ml. Fractions containing EF-2
were identified as above. Aliquots were adjusted to a final concentration of
2 mM DTT, 5% glycerol, and stored at  70 C. Purified EF-2 was  80%
homogeneous as resolved by 7% SDS-PAGE and stained with colloidal
Coomassie (Invitrogen). Protein concentration was determined by Bradford
Assay according to standard protocols using Coomassie Protein Assay Re-
agent (Pierce Chemical Co.).
Purification of early endosomes
Early endosomes were isolated from HUT102/6TG cells according to a proto-
col by Duprez and Dautry-Varsat (1986). The early endosomal compartment
was loaded with 1  M DAB389IL-2, 1  M DA189(VSV-G)B389IL-2, 8 mg/ml 70-kD
SNARF1-dextran conjugate (Molecular Probes, Inc.), and/or 5 mg/ml HRP
(Sigma-Aldrich) using 1  M bafilomycin A1–primed cells (Sigma-Aldrich).
Purification of HUT102/6TG CTF complex
Crude cytosolic extract was isolated from HUT 102/6TG cells according
to the protocol modified from Bomsel et al. (1990). In brief, cells were
washed three times with cold PBS containing 5 mg/ml BSA, once with
cold PBS alone, and twice with cold cytosol buffer (CB; 3% sucrose in
100 mM Hepes-KOH, pH 7.9, 1.4 M KCl, 30 mM MgCl2, 2 mM EDTA,
and 5 mM DTT). Cells were lysed by 20 passages through a 25 G needle
in CB containing protease inhibitors as follows: 10  g/ml aprotinin, 1
 g/ml pepstatin, 1  g/ml antipain, and 1  m PMSF (all obtained from
Sigma-Aldrich) The lysate was centrifuged at 1,000 g for 15 min at 4 C.
The post-nuclear supernatant was then centrifuged at 170,000 g for 1 h
at 4 C. The supernatant fraction was dialyzed overnight at 4 C against
cytosol dialysis buffer (CDB; 1% sucrose in 20 mM Tris-HCl, pH 8.0, 2
mM EDTA, and 2 mM 2-ME) containing protease inhibitors as described
in CB.
Crude cytosol was fractionated according to standard chromatographic
protocols. In brief, crude extract was loaded onto an in-house packed
DEAE-Sepharose (Reactifs IBF) XK 26 column (Amersham Biosciences) for
anion exchange chromatography. A peristaltic FPLC pump (P-1; Amer-
sham Biosciences) and Single Path Monitor (UV-1; Amersham Bio-
sciences) were used during chromatography. The column was preequili-
brated with buffer B3 (containing 50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 5
mM 2-mercaptoethanol, and 1  g PMSF per ml), and “loaded” sample was
washed using the same buffer. CTFs were eluted with a linear gradient,
0–400 mM NaCl, in buffer B3 at a flow rate of 5 ml/min. Fractions containing
CTFs were identified using an in vitro translocation assay and in vitro ribo-
sylation assay in series (see Materials and methods). Fractions containing
in vitro translocation activity eluted between 150 to 190 mM NaCl, and
were pooled and concentrated using Centriplus Centrifugal Filters (YM-10;
Amicon) according to manufacturer’s directions. Protein concentration
was determined as described by Bradford assay.
Next, CTFs were fractionated by size exclusion chromatography using
Sephacryl
® S200 (Amersham Biosciences) XK 26 column (Amersham Bio-
sciences) equilibrated with buffer B3. A Single Path Monitor (UV-1; Amer-
sham Biosciences) was used to monitor chromatography. Sample loads of
5 ml were isocratically eluted in buffer B3. Flow rate was gravitationally
determined at  2 ml per min. Resolution of the mobile phase was moni-
tored by 7–12% SDS-PAGE and staining with colloidal Coomassie. CTFs
were identified using an in vitro translocation assay and an in vitro ribosy-
lation assay in series, and correlated with elution of 100 to 250 kD sized
proteins, but contained proteins as small as 20–25 kD when visualized by
7%-12% SDS-PAGE and stained with colloidal Coomassie.
Partially purified CTFs were further purified by anion exchange chroma-
tography using a column (Mono Q HR 5/5; Amersham Biosciences) on an
HPLC (Biosys2000; Beckman Coulter). The column was preequilibrated
with buffer B4 (containing 50 mM Tris-HCl, pH 8.0, and 1 mM EDTA).
Sample loads of 2 ml were washed using buffer B4 and CTFs were eluted
using serial hyperbolic step gradients, 0 to 1.0 M NaCl, in buffer B4 at a
flow rate 2 ml/min. CTFs were identified using an in vitro translocation as-
say and an in vitro ribosylation assay in series and eluted at a conductance
of 27.3 mS. Translocation in vitro-competent fractions were pooled, dia-
lyzed against 50 mM Tris-HCl, pH 7.4, and 1% sucrose overnight at 4 C,
and then concentrated using Microcon Centrifugal Filters (YM-10; Ami-
con) according to manufacturer’s directions. Protein concentration was de-
termined as by Bradford assay. Controls indicated that the purified CTF
complex had no intrinsic ADP-ribosyltransferase activity.
Purification of NLY22
  CTF complex
Yeast crude cytosolic extract was isolated using the same procedure de-
scribed above for HUT 102/6TG cells, except NLY22
  cells were lysed by
vortexing cells with 212–300 micrometer glass beads (Sigma-Aldrich). Cell
lysis was monitored by decrease in exclusion of Trypan Blue dye (GIBCO
BRL). Controls indicated that the purified CTF complex had no intrinsic
ADP-ribosyltransferase activity.
In vitro translocation assay
Translocation of the C-domain was performed using protocol modified by
Lemichez et al. (1997) as follows: 25- l reaction mixtures containing 4  l
early endosomes in translocation buffer (TB; 50 mM Tris-HCl, pH 7.4, and
25 mM EDTA). For reducing conditions, TB contained 20 mM DTT. For
nonreducing conditions, TB contained 10  M NADPH (Qbiogene). ATP
and cytosol were added to 2 mM and 5.0 to 0.09  g/ l as indicated, re-
spectively. Translocation mixtures were incubated at 37 C for 30 min, and
the supernatant fluid and pellet were separated by ultracentrifugation at
180,000 g at 4 C for 20 min. The pellet fraction was resuspended in 25  l
TB containing 0.2% Triton X-100 (Sigma-Aldrich), and both the lysed pel-
let and supernatant fluid were boiled for 5 min. The inhibitors geldanamycin
(Alomone Labs), radicicol (Sigma-Aldrich), cis-13-retinoic acid (Sigma-
Aldrich), and trans-13-retinoic acid (Sigma-Aldrich) were added as indi-
cated. hrHsp 90 (StressGen Biotechnologies), brTrR-1 (American Diagnostica,
Inc.), and hrTrx (American Diagnostica, Inc.) were added as indicated. The
membrane integrity of purified early endosomes in the assay system was
verified using HRP as described by Lemichez et al. (1997).
In vitro ADP-ribosylation assay
The in vitro NAD
 -dependent ADP-ribosylation of EF-2 was performed
according to a protocol by Chung and Collier (1977). Reaction mixtures
contained 3 pM [
32P]-NAD
  (800  Ci/mmol; Dupont-NEN Life Science
Products), and when indicated 1 mM ATP and/or 0.5 mg/ml crude
HUT102/6TG cytosol. Where indicated, autoradiographic signals on
X-OMAT AR film (Kodak) were analyzed by ImageQuant™ software (Mo-
lecular Dynamics) and Kodak ID software (Kodak) according to manufac-
turer’s directions.
Immunoprecipitation and affinity chromatography
Immunoprecipitation of human Hsp 90 (both   and  ), yeast Hsp 82, and
human TrR-1 were performed according to standard protocols using rabbit
IgG polyclonal anti–human Hsp 90 antibodies (Santa Cruz Biotechnology,
Inc.), rabbit polyclonal anti-Hsp82 antiserum (a gift from S. Lindquist, Mas-
sachusetts Institute of Technology, Cambridge, MA), and rabbit polyclonal
anti–human TrR-1 antibodies (Upstate Biotechnology). Antibody was first
cross-linked to Protein A Agarose (Santa Cruz Biotechnology, Inc.) before
immunoprecipitation. In each instance, 2–4  g rabbit polyclonal was in-
cubated with 100  l or 200  l of resuspended volume of Protein A Aga-
rose in 50 mM Tris-HCl and 1 mM EDTA containing 1% NP-40 and 100T
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mM NaCl on a rocker overnight at 4 C. Bound antibody was collected by
centrifugation at 1,000 g for 5 min at 4 C, and washed 2  with 10  cur-
rent volume with 0.2 M sodium borate (Sigma-Aldrich), pH 9.0, for 5 min
at 25 C. Dimethyl Pimelimidate.2HCl (Sigma-Aldrich) was added to a final
concentration of 20 mM, and the reaction mixture was incubated for
30 min at 25 C. Cross-linked antibody was pelleted by centrifugation at
1,000 g for 5 min at 4 C, and the pellet was washed 2  with 10  current
volume 0.2 M ethanolamine (Sigma-Aldrich) for 30 min at 25 C, and 2 
with PBS for 30 min at 25 C.
Immunoprecipitations using the cross-linked antibody agarose conju-
gates were performed according to standard protocols. In brief, 200  l of
Mono Q partially purified CTFs ( 0.1  g/ l) in 50 mM Tris-HCl and 1%
sucrose, containing 1% NP-40 and 25 mM NaCl, was incubated with 20
 l of antibody-agarose conjugate on a rocker overnight at 4 C. Immuno-
precipitates were collected by centrifugation at 1,000 g for 5 min at 4 C,
and supernatant fluid was evaluated in the in vitro translocation assay. Pel-
let was washed 3  with 100  l cold 50 mM Tris-HCl and 1 mM EDTA
containing 1% NP-40 and 50 mM NaCl, and resuspended in 50  l 1 
SDS-PAGE loading buffer and boiled for 5 min. Antibody-agarose beads
were pelleted by centrifugation at 1,000 g for 5 min at 25 C and the super-
natant was analyzed by 10% SDS-PAGE, stained with colloidal Coo-
massie, and selected bands were evaluated by LC-MS/MS.
Yeast TrR-1 was affinity purified using 2 ,5  ADP-Sepharose agarose
(Amersham Biosciences) using a protocol modified from Hunt et al.
(1983). In brief, 20  g of 2 ,5  ADP-Sepharose agarose was washed 2 
with 200  l 50 mM Tris-HCl and 1 mM EDTA for 20 min. Mono Q par-
tially purified CTFs (200  l of  0.1  g/ l) in 50 mM Tris-HCl, 1 mM
EDTA, 1% sucrose, and 25 mM NaCl was incubated with 2 ,5  ADP-
Sepharose on a rocker overnight at 4 C. Affinity-purified TrR-1 was col-
lected by centrifugation at 1,000 g for 5 min at 4 C. The supernatant fluid
was assayed for translocation activity in vitro. The pellet was washed 2 
in 100  l 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 1% sucrose, and
was then resuspended in 50  l 50 mM Tris-HCl, pH 7.5, 1 mM EDTA,
and 1% sucrose containing 20  M NADPH and incubated for 2 h at
25 C. The supernatant fluid was collected after centrifugation at 1,000 g
for 5 min at 4 C, and the supernatant fluid was analyzed by 10% SDS-
PAGE, stained with colloidal Coomassie, and selected bands were evalu-
ated by LC-MS/MS.
Western blots
Confirmation of CTF identification by MS was performed by Western blot
analysis according to standard protocols. In addition to using antibodies
(see Immunoprecipitation and affinity chromatography), horse polyclonal
anti-DT antibody (Massachusetts Antitoxin and Vaccine Laboratories) was
used. In brief, samples were analyzed by 7–12% SDS-PAGE, transferred to
Immobilon-P (Millipore), probed with the appropriate primary and second-
ary antibodies, and detected using either 3,3 -DAB (Sigma-Aldrich) or ECL
(Amersham Biosciences) according to the manufacturer’s directions.
In-gel reduction, alkylation, and digestion of partially purified CTFs
The preparation of partially purified CTFs for identification by MS was
performed using a modified procedure from Shevchenko et al. (1996). In
brief, partially purified CTFs were separated by 10% SDS-PAGE, stained
with colloidal Coomassie, and selected bands were excised and chopped
into small pieces. Gel pieces were washed 3  in 50 mM ammonium bi-
carbonate (Sigma-Aldrich) in 50% acetonitrile (ACN; Acros) for 20 min at
25 C. Gel pieces were washed with 100% ACN for 10 min at 25 C. Su-
pernatant was discarded, and the gel pieces were dried in a SpeedVac
®
for 15 min. Gel pieces were reduced in 20 mM DTT, 50 mM ammonium
bicarbonate, and 5% ACN for 1 h at 55 C. Supernatant was discarded
and the pieces were washed with 100  l 50 mM ammonium bicarbonate
for 10 min at 25 C and subsequently with 100  l 100% ACN for 10 min
at 25 C.
Gel pieces were alkylated in 100  l 100 mM iodoacetamide (ICN Bio-
medicals) and 50 mM ammonium bicarbonate for 30 min in the dark at
25 C. Supernatant was discarded and the pieces were washed with 100  l
50 mM ammonium bicarbonate for 10 min at 25 C and subsequently dried
with 100  l 100% ACN for 10 min at 25 C. The washing and drying steps
were repeated before drying the pieces in a SpeedVac
® for 15 min.
Gel pieces were rehydrated in digestion buffer (50 mM ammonium bi-
carbonate) and MS Sequencing Grade Trypsin (Roche) at an estimated
1:100 enzyme to substrate ratio on ice for 45 min. 50 mM Ammonium bicar-
bonate was added when necessary to keep the gel pieces wet. Digestions
were incubated for 6–8 h at 37 C. Peptides were extracted from the gel
pieces using 100  l 20 mM ammonium bicarbonate for 20 min, followed
by 2  200  l 1% TFA in 50% ACN for 20 min, and finally 1  100  l
100% ACN for 10 min. Supernatant fluids were pooled and dried in a
SpeedVac
®. The pellets were resuspended in 0.1% TFA and desalted using
ZipTip
®
C18 pipette tips (Millipore) according to manufacturer’s directions.
Capillary HPLC of tryptic peptides
HPLC was performed using a capillary LC system (LC Packings; Dionex
Corp.) composed of a Famous autosampler, a Switchos microcolumn
switching unit and an Ultimate pump. Sample loads of 5  l were precon-
centrated and desalted online with a “small molecule” C18 CapTrap™
(Michrom BioResources) using a solution of 5% FA and 0.1% TFA at a
flow rate of 50  l per min for 4 min. Capillary HPLC columns were pre-
pared in house as follows: 300  m ID   15-cm fused silica capillaries
were pressure bomb–packed (Mass Evolution, Inc.) at 2,000 PSI with
Magic C18 3- m 200 Å pore-reversed phase-packing material (Michrom
BioResources) using 2-propanol as a carrier solvent. Columns were
washed with 10% acetic acid, followed by methanol, then the HPLC mo-
bile phase before use at a flow rate of 2  l per min. Elution was by linear
gradient; 95% A (5% ACN, 0.1% formic acid) to 55% B (85% ACN, 10%
2-propanol, 0.1% formic acid) over 50 min followed by 60 min of col-
umn regeneration.
MALDI and ESI MS, tandem MS, and LC-MS/MS
MALDI MS was acquired in positive polarity on a mass spectrometer (Re-
flex IV; Bruker) with delayed extraction in the reflectron mode using a UV
nitrogen laser. A laser power of 28–45% was used, and 50–100 laser shots
were summed for each spectrum. The matrix used was 2,5-dihydroxyben-
zoic acid (Sigma-Aldrich). Data were analyzed using BioAnalyst™ (Ap-
plied Biosystems) reconstruction algorithms. For initial screening and
searches, acquired mass values were compared with theoretical protein di-
gests using the Mascot search engine (Matrix Science, Ltd.). Reported
scores, based on a probability of match, were statistically significant for
each protein identified in Table I.
ESI MS and MS/MS were performed using an ESI quadrupole/orthogonal
acceleration time-of-flight mass spectrometer (QSTARi
® Pulsar; Applied
Biosystems). MS and MS/MS were acquired in the positive polarity mode
over the range of m/z 320–1800 (MS) and m/z 100–1800 (MS/MS) with
resolution  1:9,000 (full width half maximum) and better than 50 ppm
mass accuracy (external calibration). For nanospray, a Protana source was
used using uncoated glass nanospray tips pulled in house to 1  m ID using
a capillary puller (Sutter Instrument Co.) ESI was initiated at  1,200 V via
a Pt wire inserted into the glass tip. Tandem mass spectra were acquired
using Ar as the collision gas and sufficient collision energy to obtain com-
plete sequence information of the precursor. Pulsed ion enhancement of
product ions was used for MS/MS of low S/N precursors. For LC-MS, the
LC was coupled to the mass spectrometer using 50  m ID distal coated
nanospray tips pulled to 15  m ID, 75  m OD at the tip (New Objectives
Inc.). ESI was performed at 4,500 V. Information-dependent acquisition
was used to obtain MS/MS spectra of peaks during elution from the LC sys-
tem. MS peaks that exceeded a threshold of 10 counts/s were subjected to
MS/MS using preset collision energies proportional to the m/z value of the
precursor ( 18–60 V, lab frame). Pulsed ion enhancement was used for all
LC-MS/MS spectra.
Cytotoxicity assays
Cytotoxicity assays for the fusion protein toxins were performed essen-
tially as described by vanderSpek et al. (1994). Cytotoxicity assays to
evaluate the affects of geldanamycin, radicicol, and retinoic acid on
DAB389IL-2 intoxication were modified from vanderSpek et al. (1994) as
such: cells were seeded at 5   10
4 cells per well and preincubated with
inhibitors geldanamycin, radicicol, cis-13-retinoic acid, for 30 min at
37 C, 5% CO2 and subsequently incubated with varying concentrations
of DAB389IL-2 and inhibitor for 15 min at 37 C, 5% CO2. Cells were pel-
leted and washed free of toxin with media containing inhibitor and incu-
bated for 8–12 h at 37 C, 5% CO2. Cells were then washed and pulsed
with minimal media (leucine depleted; BioWhittaker) containing [
14C]leu-
cine (NEN Life Science Products) for 2 h at 37 C, 5% CO2, and protein
synthesis was analyzed according to vanderSpek et al. (1994). Media
alone and media plus inhibitor alone served as controls. Assays were per-
formed in quadruplicate.
Online supplemental material
Table of peptide coverage from LC-MS/MS is available as online supple-
mental material at http://www.jcb.org/cgi/content/full/jcb.200210028/DC1.
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